CA2619663A1 - Human ribosomal dna(rdna) and ribosomal rna (rrna) nucleic acids and uses thereof - Google Patents

Human ribosomal dna(rdna) and ribosomal rna (rrna) nucleic acids and uses thereof Download PDF

Info

Publication number
CA2619663A1
CA2619663A1 CA002619663A CA2619663A CA2619663A1 CA 2619663 A1 CA2619663 A1 CA 2619663A1 CA 002619663 A CA002619663 A CA 002619663A CA 2619663 A CA2619663 A CA 2619663A CA 2619663 A1 CA2619663 A1 CA 2619663A1
Authority
CA
Canada
Prior art keywords
nucleic acid
nucleotide sequence
rrna
molecule
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002619663A
Other languages
English (en)
French (fr)
Inventor
Denis Drygin
Emil Michelotti
Sean O'brien
William G. Rice
Adam Siddiqui-Jain
Jeffrey P. Whitten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of CA2619663A1 publication Critical patent/CA2619663A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002619663A 2005-08-19 2006-08-18 Human ribosomal dna(rdna) and ribosomal rna (rrna) nucleic acids and uses thereof Abandoned CA2619663A1 (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US70959805P 2005-08-19 2005-08-19
US60/709,598 2005-08-19
US73246005P 2005-11-01 2005-11-01
US60/732,460 2005-11-01
US75159305P 2005-12-19 2005-12-19
US60/751,593 2005-12-19
US77592406P 2006-02-22 2006-02-22
US60/775,924 2006-02-22
US77932706P 2006-03-02 2006-03-02
US60/779,327 2006-03-02
US78380106P 2006-03-16 2006-03-16
US60/783,801 2006-03-16
US78910906P 2006-04-03 2006-04-03
US60/789,109 2006-04-03
PCT/US2006/032508 WO2007022474A2 (en) 2005-08-19 2006-08-18 HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF

Publications (1)

Publication Number Publication Date
CA2619663A1 true CA2619663A1 (en) 2007-02-22

Family

ID=37758472

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002619663A Abandoned CA2619663A1 (en) 2005-08-19 2006-08-18 Human ribosomal dna(rdna) and ribosomal rna (rrna) nucleic acids and uses thereof

Country Status (5)

Country Link
US (2) US20070117770A1 (enExample)
EP (1) EP1926372A2 (enExample)
JP (1) JP2009504192A (enExample)
CA (1) CA2619663A1 (enExample)
WO (1) WO2007022474A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100063046A1 (en) * 2006-05-17 2010-03-11 Whitten Jeffrey P Tetracyclic imidazole analogs
US8278057B2 (en) * 2007-09-14 2012-10-02 Nestec S.A. Addressable antibody arrays and methods of use
KR101601332B1 (ko) * 2007-10-05 2016-03-08 센화 바이오사이언시즈 인코포레이티드 퀴놀론 유사체 및 이와 관련된 방법
EP2277032A4 (en) * 2008-05-09 2011-10-26 Zhiping Liu SYSTEM FOR THE DETECTION OF MOLECULES
JP5768282B2 (ja) 2008-12-10 2015-08-26 ユニヴァーシティ オブ ワシントン ｒＲＮＡ前駆体のレシオメトリック分析
KR20120013371A (ko) * 2009-05-15 2012-02-14 베링거 인겔하임 인터내셔날 게엠베하 ＮｏＣＲ의 발현이 감소된 개선된 세포주 및 이의 용도
KR100998365B1 (ko) * 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
WO2012123938A1 (en) * 2011-03-17 2012-09-20 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
EP3074391B1 (en) 2013-11-28 2019-07-31 Tel Hashomer Medical Research Infrastructure And Services Ltd. Rna polymerase i inhibitors and uses thereof
CN119185322A (zh) 2015-11-20 2024-12-27 生华生物科技股份有限公司 用于治疗癌症的四环喹诺酮类似物组合疗法
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
ES2959536T3 (es) * 2015-12-14 2024-02-26 Senhwa Biosciences Inc Formas cristalinas de análogos de quinolona y sus sales
WO2017190145A1 (en) 2016-04-29 2017-11-02 Icahn School Of Medicine At Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
EP3752149A4 (en) 2018-02-15 2022-03-02 Senhwa Biosciences, Inc. QUINOLONE ANALOGUES AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE
CN118459539B (zh) 2021-03-19 2026-01-06 生物治疗探索股份有限公司 用于调节训练免疫的化合物及其使用方法
WO2023025161A1 (zh) * 2021-08-23 2023-03-02 北京嘉树佳业科技有限公司 来源于药用植物的sRNA及其应用
IL328679A (en) * 2023-11-28 2026-07-01 Genome Therapeutics Ltd Tetracyclic compounds for use in antibody-drug conjugates for cancer treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723597A (en) * 1983-01-10 1998-03-03 Gen-Probe Incorporated Ribosomal nucleic acid probes for detecting organisms or groups of organisms
US5641631A (en) * 1983-01-10 1997-06-24 Gen-Probe Incorporated Method for detecting, identifying, and quantitating organisms and viruses
US5681698A (en) * 1991-04-25 1997-10-28 Gen-Probe Incorporated 23S rRNA nucleic acid probes to mycobacterium kansasii
NZ287139A (en) * 1994-06-14 1997-07-27 Dainippon Pharmaceutical Co Naphthyridine derivatives; preparative process and anti-tumour medicaments
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
AU744873B2 (en) * 1996-11-06 2002-03-07 Regents Of The University Of California, The Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof
US20050191661A1 (en) * 1996-11-06 2005-09-01 Tetsuya Gatanaga Treatment of inflammatory disease by cleaving TNF receptors
US6930084B1 (en) * 1996-11-06 2005-08-16 The Regents Of The University Of California Treating arthritis with TNF receptor releasing enzyme
US7138384B1 (en) * 1997-08-29 2006-11-21 The Regents Of The University Of California Modulators of DNA cytosine-5 methyltransferase and methods for use thereof
AU2657499A (en) * 1998-02-04 1999-08-23 Board Of Regents, The University Of Texas System Synthesis of quinobenzoxazine analogues with topoisomerase ii and quadruplex interactions for use as antineoplastic agents
US6911314B2 (en) * 1999-05-14 2005-06-28 The Regents Of The University Of California Screening for drugs that affect TNF receptor releasing enzyme
US20030204075A9 (en) * 1999-08-09 2003-10-30 The Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
WO2002012331A2 (en) * 2000-08-07 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
US20030166213A1 (en) * 2000-12-15 2003-09-04 Greenspan Ralph J. Methods for identifying compounds that modulate disorders related to nitric oxide/ cGMP-dependent protein kinase signaling
US6645749B2 (en) * 2001-05-25 2003-11-11 Novozymes A/S Lipolytic enzyme
WO2003087317A2 (en) * 2002-04-05 2003-10-23 Cyternex, Inc. Methods for targeting quadruplex dna
AU2003272389A1 (en) * 2002-09-12 2004-04-30 Cyternex, Inc. Expanded porphyrin compositions for tumor inhibition
US7354916B2 (en) * 2003-04-07 2008-04-08 Cylene Pharmaceuticals Substituted quinobenzoxazine analogs
US20040115706A1 (en) * 2003-09-11 2004-06-17 Jin Cheng He High-throughput methods for identifying quadruplex forming nucleic acids and modulators thereof
ATE451924T1 (de) * 2004-03-15 2010-01-15 Sunesis Pharmaceuticals Inc Sns-595 und anwendungsverfahren

Also Published As

Publication number Publication date
EP1926372A2 (en) 2008-06-04
WO2007022474A3 (en) 2007-12-21
JP2009504192A (ja) 2009-02-05
WO2007022474B1 (en) 2008-02-14
WO2007022474A2 (en) 2007-02-22
US20070117770A1 (en) 2007-05-24
US20090181377A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
US20090181377A1 (en) HUMAN RIBOSOMAL DNA (rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF
US20110112086A1 (en) Pyridinone analogs
US10450564B2 (en) Micromirs
US20100305136A1 (en) Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
ES2629339T3 (es) Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
CN103180445B (zh) 通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病
US20100197772A1 (en) Tissue-Specific MicroRNAs and Compositions and Uses Thereof
EP0929689A2 (en) Artifical chromosomes, uses thereof and methods for preparing artificial chromosomes
US20120263740A1 (en) Aptamer-targeted sirna to inhibit nonsense mediated decay
US7960102B2 (en) Regulated aptamer therapeutics
TW201143782A (en) Treatment of LIM homeobox 2 (LHX2) related diseases by inhibition of natural antisense transcript to LHX2
KR20240034746A (ko) 하이드록시산 산화효소 1(hao1)을 표적으로 하는 rna 가이드를 포함하는 유전자 편집 시스템 및 이의 용도
US20030166213A1 (en) Methods for identifying compounds that modulate disorders related to nitric oxide/ cGMP-dependent protein kinase signaling
KR20130017309A (ko) 안티센스 올리고뉴클레오타이드를 포함하는 줄기세포로부터 연골세포 분화 촉진용 및 항암 약제학적 조성물
EP4077672A1 (en) Enhanced oligonucleotides for inhibiting scn9a expression
AU2013273821B2 (en) Micromirs
WO2005074988A1 (ja) 神経細胞分化誘導剤

Legal Events

Date Code Title Description
FZDE Discontinued